LY2605541: Additional Phase II data

Additional data from 108 Type I diabetics who completed treatment in an open-label, crossover, U.S. and Israeli Phase II trial showed that once-daily subcutaneous LY2605541 significantly reduced total daily insulin use by 20.7% compared to Lantus insulin glargine at week 8 (p=0.005). Compared to Lantus, LY2605541 also significantly reduced mealtime insulin use at breakfast by 13.7% (p=0.021), at lunch by 18.6% (p<0.001) and at dinner by 22.4% (p<0.001). Patients treated with LY2605541 had a higher overall hypoglycemia rate vs. Lantus (9.2 vs. 8.1 events/30 days), but a lower rate of nocturnal hypoglycemia (0.9 vs. 1.2 events/30 days). Data were presented at the American Diabetes Association meeting in Chicago. Previously reported data showed that LY2605541 plus mealtime insulin significantly reduced daily mean blood glucose from baseline to week 8 vs. Lantus plus mealtime insulin (144 vs. 152 mg/dL, p<0.001) (see BioCentury June 18, 2012). ...